Gadopentetate dimeglumine Other names: Gadopentetic acid Gd-DTPA

Patients with seizure disorders or with intracranial lesions may be at higher risk of developing seizure activity, as has been reported rarely in association with gadopentetic acid administration. For patients with a predisposition to seizures, preventive measures should be taken, e.g. close monitoring, equipment and drugs necessary to treat seizures should they occur should be ready for use in advance.

For gadopentetic acid, dimeglumine no clinical study data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal development.

No data exist concerning intra-articular administration in lactating women. After intravascular use minimal amounts of gadopentetic acid, dimeglumine salt (a maximum of 0.04%) of the intravenously administered dose enters the breast milk. From experience gained so far, harm to the breast-fed infant is considered unlikely.

No effects of gadopentetic acid on driving ability and use of machinery can be expected. However, joint effusion may affect the ability to drive due to a limited joint mobility.